Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.

@article{Bristol2001AdenovirusmediatedFV,
  title={Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.},
  author={Jillian A Bristol and A M Gallo-Penn and Julie L Andrews and Neeraja Idamakanti and Michael Kaleko and S Connelly},
  journal={Human gene therapy},
  year={2001},
  volume={12 13},
  pages={1651-61}
}
Hemophilia A patients are typically treated by factor VIII (FVIII) protein replacement, an expensive therapy that induces FVIII-specific inhibitors in approximately 30% of patients with severe hemophilia. FVIII gene therapy has the potential to improve the current treatment protocols. In this report, we used a hemophilia A mouse model to compare the humoral and cellular immune responses between an E1/E2a/E3-deficient adenovirus expressing human FVIII directed by a liver-specific albumin… CONTINUE READING